Other targeted therapies or combinations of therapies for glioma have not made significant progress: tyrosine kinase inhibitors targeting the EGFR alone or in combination with TMZ failed to significantly improve prognosis [16]. This evidence concerns the gene EGFR and central nervous system cancer.